Spectrum Solutions, backed by private equity firm DW Healthcare Partners, announced on March 7 its acquisitions of Alimetrix, Inc. and Microarrays, Inc., both of which are based in Huntsville, Alabama.
These assets, combined with Spectrum Solutions core competencies of providing industry leading contract manufacturing services and unique biospecimen collection devices, results in a portfolio of products and services that accelerates Spectrum’s go-to-market strategies and enhances the overall patient testing experience whether in a clinical setting or at home. Terms of the deal were not disclosed.
Alimetrix, Inc. is a CLIA and CAP accredited molecular diagnostic laboratory skilled at custom qualitative and quantitative assay development.
Founded in 1999, Microarrays, Inc. is a leader in customer array-based products that are used as biological research tools – gene expression arrays, reverse and forward phase protein arrays.
Spectrum Solutions, a life science company, focuses its fully-integrated industry expertise on creating forward-looking end-to-end solutions for clinical diagnostic projects and commercialized product plans. Spectrum is a single-source provider for innovative medical device engineering and product manufacturing, molding, formulation, packaging design, customized kitting and direct-to-user fulfillment. DW Healthcare Partners acquired Spectrum Solutions in June 2019.
According to data captured in the LevinPro HC database, this acquisition represents the 24th Laboratories, MRI and Dialysis transaction of 2023 and the 14th in the diagnostics subsector. There were 28 Laboratories, MRI and Dialysis deals, including 24 diagnostics acquisitions, announced between January 1, 2022, and March 7, 2022.
